Patent intelligence · US
US 11066405
Bicyclic compounds and their use in the treatment of cancer
Bicyclic compounds and their use in the treatment of cancer
Patent details — US 11066405
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 20, 2021
- Expiration
- Jul 15, 2041
- Applicant
- TEMPEST THERAPEUTICS, INC.
- Claims
- 16
- CPC classes
- A61P, A61P35/00
Quick answer
US 11066405 (Bicyclic compounds and their use in the treatment of cancer) is held by TEMPEST THERAPEUTICS, INC.. Status: granted. Granted Jul 20, 2021. Expires Jul 15, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEMPEST THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61P, A61P35/00
More from TEMPEST THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12215093
Bicyclic carboxamides and methods of use thereof
granted -
US 11795156
Bicyclic carboxamides and methods of use thereof
granted -
US 11738009
Bicyclic compounds and their use in the treatment of cancer
granted -
US 11666557
Triazolone compounds and uses thereof
granted -
US 11638704
Bicyclic compounds and their use in the treatment of cancer
granted -
US 11472789
Bicyclic carboxamides and methods of use thereof
granted -
US 10968201
Bicyclic carboxamides and methods of use thereof
granted
Frequently asked questions
What is US patent 11066405?
US 11066405 (Bicyclic compounds and their use in the treatment of cancer) is held by TEMPEST THERAPEUTICS, INC.. Status: granted. Granted Jul 20, 2021. Expires Jul 15, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11066405?
TEMPEST THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 11066405 expire?
Our index shows an expiration date of Jul 15, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.